Quadrant Capital Group LLC Raises Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Quadrant Capital Group LLC raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 22.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,414 shares of the biopharmaceutical company’s stock after buying an additional 624 shares during the period. Quadrant Capital Group LLC’s holdings in Halozyme Therapeutics were worth $126,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Principal Securities Inc. purchased a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $34,000. First Horizon Advisors Inc. lifted its position in shares of Halozyme Therapeutics by 24.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 293 shares during the last quarter. Parkside Financial Bank & Trust purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter worth $64,000. Headlands Technologies LLC lifted its position in shares of Halozyme Therapeutics by 1,068.2% during the 4th quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 1,613 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter worth $196,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Down 0.1 %

NASDAQ HALO opened at $45.48 on Thursday. The firm’s fifty day moving average is $40.76 and its two-hundred day moving average is $38.74. Halozyme Therapeutics, Inc. has a one year low of $31.86 and a one year high of $46.16. The company has a debt-to-equity ratio of 8.44, a quick ratio of 5.36 and a current ratio of 6.64. The firm has a market cap of $5.79 billion, a PE ratio of 18.79, a P/E/G ratio of 0.51 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The company had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Analysts expect that Halozyme Therapeutics, Inc. will post 3.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HALO has been the subject of several recent analyst reports. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 23rd. TD Cowen initiated coverage on shares of Halozyme Therapeutics in a research report on Thursday, February 29th. They set an “outperform” rating and a $54.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday. JMP Securities cut their price target on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 8th. Finally, Benchmark reiterated a “buy” rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $53.14.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the sale, the senior vice president now owns 156,558 shares in the company, valued at approximately $6,519,075.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have sold 40,000 shares of company stock valued at $1,650,600. 2.40% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.